What is Recombinant DNA Vaccine?

Technology - Recombinant DNA Technology

Through recombinant DNA technology scientists alter organisms' genetic code inside laboratories to bestow new advantageous characteristics upon them. The technology combines DNA segments from multiple sources through vectors like plasmids or viruses to modify gene expression by adding or deleting genetic material. The pioneering creation of the first recombinant DNA molecules was accomplished in 1973 by scientists Paul Berg and Stanley Cohen working together with Herbert Boyer and Annie Chang. Modern biotechnology now relies fundamentally on this technology which has rapidly expanded into medicine agriculture and environmental sciences.

The fundamental process of recombinant DNA technology consists of:

The extensive application of recombinant DNA technology stems from its efficient operation and adaptable nature. Medical applications of recombinant DNA technology produce essential medications such as insulin and growth hormones while agricultural uses create pest-resistant genetically modified crops and environmental applications focus on bioremediation and pollution control efforts.

Common Applications of Recombinant DNA Vaccines

1. Hepatitis B Virus (HBV) Recombinant DNA Vaccine

The hepatitis B virus (HBV) acts as a global pathogen which results in millions of infections every year. Recombinant DNA vaccines use yeast or bacterial vectors to insert the HBV surface antigen gene so host cells can manufacture the HBsAg protein. The immune system identifies these proteins which activate protective responses through both humoral and cellular immunity.

The global health authorities first approved the hepatitis B vaccine after recombinant DNA technology was used to develop it. The recombinant hepatitis B vaccine has been serving as a global preventive standard against HBV infection since its introduction in the 1980s. The product offers effective safety and stability while delivering powerful protection against HBV for those with compromised immune systems.

Explore All HBV Products for Vaccine Development →

2. Human Papillomavirus (HPV) Recombinant DNA Vaccine

The primary factor that leads to cervical cancer development is infection with human papillomavirus (HPV). Vaccines deploy a vector to transfer the HPV L1 gene into host cells where these cells generate the L1 protein which builds virus-like particles (VLPs). VLPs mimic HPV structure without possessing infectious properties which activates neutralizing antibody production by the immune system.

Two widely used recombinant DNA vaccines provide protection against multiple high-risk HPV types and substantially decrease cervical cancer rates. These vaccine successes show how recombinant DNA vaccines can protect against cancers caused by viruses.

Explore All HPV Products for Vaccine Development →

3. Influenza Virus Recombinant DNA Vaccine

Traditional vaccine development faces challenges due to the influenza virus's high variability. Recombinant DNA vaccines work by inserting the hemagglutinin (HA) gene into a vector which leads to HA protein production in host cells. Recombinant DNA vaccines generate specific proteins which trigger the immune system to produce neutralizing antibodies that fight the influenza virus.

The production of recombinant DNA-based influenza vaccines involves the expression of the HA protein in insect cells. The new vaccine type surpasses traditional influenza vaccines because it achieves greater production efficiency and provides wider immune protection that adapts effectively to the flu virus's variability.

Browse Influenza Virus Antibodies

Browse Influenza Virus Antigens

ELISA Kits